F2G and Shionogi report positive Phase 3 results for antifungal candidate olorofim

F2G and Shionogi announced that their joint antifungal candidate, olorofim, met the primary endpoints in a Phase 3 trial. The data were released Thursday morning and showed the drug performed comparably to existing treatments.

The companies said the results give them a potentially clear regulatory pathway toward approval. No safety concerns were highlighted in the summary, suggesting a favorable risk profile.

If the trial outcomes hold up under further review, olorofim could become a new option for patients with serious fungal infections, expanding the companies' product pipelines.